Trial reportThe pharmacogenomics journal2007
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.
Trial report in The pharmacogenomics journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00563901 (GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.BMC medicine · 2013Pooled it
- Cost effectiveness of pharmacogenomics: a critical and systematic review.PharmacoEconomics · 2010Pooled it
- CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.American journal of nephrology · 2010Trial
- beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.Clinical pharmacology and therapeutics · 2008Trial
- Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).American heart journal · 2008Trial
- Indole metabolism and its role in diabetic macrovascular and microvascular complications.American heart journal plus : cardiology research and practice · 2025Review
- A Review of the Epidemiological Evidence for Adducin Family Gene Polymorphisms and Hypertension.Cardiology research and practice · 2019Review
- Hypertension pharmacogenomics: in search of personalized treatment approaches.Nature reviews. Nephrology · 2016Review
- Characteristics associated with informed consent for genetic studies in the ACCORD trial.Contemporary clinical trials · 2014Article
- Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.Pharmacogenomics · 2012Review
- Cardiovascular pharmacogenomics.Circulation research · 2011Review
- Expectations, validity, and reality in pharmacogenetics.Journal of clinical epidemiology · 2010Review
- The Pharmacogenomics of Anti-Hypertensive Therapy.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Pharmacogenomics of antihypertensive drugs: past, present and future.Pharmacogenomics · 2010Article
- Pharmacogenetics and stroke.Stroke · 2009Review
- Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment.Pharmacy world & science : PWS · 2009Article
- Pharmacogenetics of cardiovascular drug therapy.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases · 2009Article
- Ancillary risk information and pharmacogenetic tests: social and policy implications.The pharmacogenomics journal · 2008Review
- Diuretic-gene interaction and the risk of myocardial infarction and stroke.The pharmacogenomics journal · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
Abstract
In a double-blind, outcome trial conducted in hypertensive patients randomized to chlorthalidone (C), amlodipine (A), lisinopril (L), or doxazosin (D), the alpha-adducin Gly460Trp polymorphism was typed (n=36 913). Mean follow-up was 4.9 years. Relative risks (RRs) of chlorthalidone versus other treatments were compared between genotypes (Gly/Gly+Gly/Trp versus Trp/Trp). Primary outcome was coronary heart disease (CHD). Coronary heart disease incidence did not differ among treatments or genotypes nor was there any interaction between treatment and genotype (P=0.660). Subgroup analyses indicated that Trp allele carriers had greater CHD risk with C versus A+L in women (RR=1.31) but not men (RR=0.91) with no RR gender differences for non-carriers (gender-gene-treatment interaction, P=0.002). The alpha-adducin gene is not an important modifier of antihypertensive treatment on cardiovascular risk, but women Trp allele carriers may have increased CHD risk if treated with C versus A or L. This must be confirmed to have implications for hypertension treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.